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[57] ABSTRACT 
Certain novel heterocyclic compounds, aromatic thio-
esters, their preparation, and their use in inhibiting ser-
ine proteases with chymotrypsin-like and elastase-like 
specificity and in the treatment of diseases such as em-
physema which involve tissue proteolysis. 




THIOESTER INHIBITORS OF SERINE 
PROTEASES 
pounds inhibit the serine proteases by reversibly block-
ing the enzyme and may be used in vivo to treat diseases 
resulting from tissue destruction due to elastase, chymo-
trypsin and related enzymes. They may be used in vitro 
BACKGROUND OF THE INVENTION 5 to prevent proteolysis that occurs during the produc-
tion, isolation, purification, storage, and transport of 
peptides and proteins. The novel fluorinated anthranilic 
acid thioesters have the following structural formula: 
This invention relates to a novel class of heterocyclic 
and aromatic compounds useful for selectively inhibit-
ing elastase, selectively inhibiting chymotrypsin-like 
enzymes, or for generally inhibiting serine proteases of 
the elastase and chymotrypsin class. Certain clinical 10 
symptoms found in pancreatitis, emphysema, rheuma-
toid arthritis, inflammation, and adult respiratory dis-
tress syndrome are believed to be caused by uncon-
trolled elastase in the affected tissues. Likewise, similar 
clinical symptoms found in the same diseases are be- 15 
lieved to be caused by uncontrolled cathepsin G, mast 
cell chymase, and other chymotrypsin-like enzymes. In 
vitro, proteolysis by serine proteases of the elastase and 
chymotrypsin families is often a severe problem in the 
production, isolation, purification, transport and stor- 20 
age of valuable peptides and proteins. 
It is an object of this invention to find a novel group 
of specific inhibitors for elastase, chymotrypsin and 
other serine proteases of similar substrate specificity. 
Chymotrypsin and chymotrypsin-like enzymes nor- 25 
mally cleave peptide bonds in proteins and peptides 
where the amino acid residue on the carbonyl side of 
the split bond (P1 residue) is typically Trp, Tyr, Phe, 
Met, Leu or other amino acid residues which contain 
aromatic or large alkyl side chains. Elastase and elas- 30 
tase-like enzymes, on the other hand, cleave peptide 
bonds where the P1 amino acid residue is much smaller, 
typically Ala, Val, Ser, Leu and other similar amino 
acids. All of the above enzymes have extensive second-
ary specificity and recognize amino acid residues re- 35 
moved from the P1 residue. The inhibitors of this inven-
tion would be useful for treating diseases such as pan-
creatitis, emphysema, rheumatoid arthritis, adult respi-
ratory distress syndrome, and inflammatory diseases 
which involve destruction of tissue by serine proteases. 40 
In some cases, it would be more useful to utilize a spe-
cific elastase or chymotrypsin-like enzyme inhibitor, 
while in other cases an inhibitor with broader specific-
ity would be appropriate. 
It is an object of this invention to find a novel group 45 
of specific inhibitors useful in vitro for inhibiting elas-
tase, chymotrypsin and other serine proteases of similar 
specificity. Such inhibitors could be used to identify 
new proteolytic enzymes encountered in research. 
They could also be used in research and industrially to 50 
prevent undesired proteolysis that occurs during the 
production, isolation, purification, transport and stor-
age of valuable peptides and proteins. Such proteolysis 
often destroys or alters the activity and/or function of 
the peptides and proteins. Uses would include the addi- 55 
tion of the inhibitors to antibodies, enzymes, plasma 
proteins, or other proteins which are widely sold for use 
in clinical analysis, biomedical research, and for many 
other reasons. For some uses a specific inhibitor would 
be desirable, while in other cases, an inhibitor with 60 
general specificity would be preferred. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Certain fluorinated acyl anthranilic acid thioesters 65 
have been found to be excellent inhibitors of human 
leukocyte elastase, porcine pancreatic elastase, bovine 
chymotrypsin and human cathepsin G. These com-
wherein 
R' is selected from the group consisting of C1-6 alkyl 
(such as ethyl, 2-methylpropyl, 2-methylbutyl, and 
3-methylbutyl) and C1.4 alkyl with an attached 
phenyl group (such as benzyl and 3-phenylpropyl), 
X is selected from the group consisting of NH, 0, S, 
CH2, and CF2, 
Y is selected from the group consisting of CO, S, SO, 
0, CF2, NH, and CH2, 
R is selected from the group consisting of C1.s alkyl 
(such as ethyl), C1.s fluorinated alkyl (such as triflu-
oromethyl, pentafluoroethyl, and heptafluoropro-
pyl), and C1.s alkoxy (such as t-butyloxy). 
The substituents on the aromatic ring of the above 
structure must be ortho to each other and not meta or 
para. The aromatic ring could be replaced by heterocy-
clic rings such as a pyridine or a thiadiazole ring. The 
C6l4 could be replaced by a cis double bond or substi-
tuted double bond such as -CH==CH-, -CMe= 
CH-, -CMe==CMe-, (Me=methyl), or 
-CCF3==CCF3-. 
Both R and R' could contain other groups or atoms 
such as 0, or S in place of CF2 or CH2 groups as long as 
the substitution does not alter the uncharged hydropho-
bic character of R and R'. 
The following novel compounds are representative 
of the invention: 
N-trifluoroacetylanthranilic acid thioethyl ester, 
N-trifluoroacetylanthranilic acid 2-methylpropyl thio-
ester, 
N-trifluoroacetylanthranilic acid 2-methylbutyl thioes-
ter, 
N-trifluoroacetylanthranilic acid 3-methylbutyl thioes-
ter, 
N-trifluoroacetylanthranilic acid thiobenzyl ester, 
N-trifluoroacetylanthranilic acid 3-phenylpropyl thio-
ester, 
N-t-butyloxycarbonyl anthranilic acid thiobenzyl ester, 
N-acetyl anthranilic acid thiobenzyl ester, 
N-trifluoroacetyl anthranilic acid thiobenzyl ester, 
N-pentafluoropropanoyl anthranilic acid thiobenzyl 
ester, and 
N-heptafluorobutanoyl anthranilic acid thiobenzyl es-
ter. 
When R-Y-X is CF3CONH and R' is any of the noted 
groups, the thioester is a general inhibitor for both 
human leukocyte elastase (HL) and bovine chymotryp-
sin. Although these thioesters are slightly less effective 
toward porcine pancreatic (PP) elastase and cathepsin 
G, they are still capable of inhibiting these enzymes. 
The inhibition constants for the various inhibitors with 
chymotypsin, cathepsin G, PP elastase and HL elastase 
have been-measured and are published (Teshima, Grif-
fin, and Powers, J. Biol. Chem. 257, pp 5085-5091 
(1982)). The published Ki values are dissociation con-
stants of the enzyme inhibitor complex. Significant inhi-
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bition of the enzyme will occur if the inhibitor concen-
tration is chosen to be approximately equal to Ki. Essen-
tially complete inhibition of the enzyme will occur ifthe 
concentration of the inhibitor is choosen to be 10 fold or 
more times Ki. Thus the specificity or generality of the 5 
inhibition reaction can be controlled first, by choosing 
the appropriate inhibitor structure and second, by 
choice of the inhibitor concentration utilized. 
The specificity of the inhibitor can be altered by 
changing the nature of the R-Y-X group. The structures IO 
with the longer acyl groups such as heptafluorobutan-
oyl are best at inhibiting chymotrypsin. Almost all are 
equally effective at inhibiting HL elastase. Only the 
fluoroacyl derivatives inhibit cathepsin G well and only 
the acyl or fluoroacyl derivatives and not the derivative 15 
where R=t-butyloxycarbonyl inhibit PP elastase well. 
Thus changing the size, shape and nature of the acyl 
group can lead either to a very specific inhibitor or to a 
very general inhibitor. Again the specificity or general-
ity of the inhibition can be controlled by the concentra- 20 
tion utilized relative to the Ki value for the specific 
enzyme whose inhibition is desired. 
It has been found that certain heterocyclic com-
pounds will inhibit serine proteases such as elastase, 
cathepsin G and chymotrypsin by reversibly blocking 25 
the enzyme. The heterocyclic compounds of this inven-
tion are 2-substituted 4H-3,l-benzoxazin-4-ones and 
2-substituted 4-quinazolones. These compounds have 
been widely prepared for other purposes (cf. Errende, 
Oien, and Yarian, J. Org. Chem., 42, pp 12-18 (1977); 30 
Patel and Patel, J. Indian Chem. Soc., 42, pp 531-535 
(1965)). One derivative, 2-bromomethyl 4H-3,l-benzox-
azin-4-one inactivates bovine chymotrypsin by irrevers-
ibly alkylating methionine-192 of the enzyme (cf. Alaz-
ard, Bechet, Dupaix, and Yon, Biochim., Biophys. 35 
Acta, 309, pp 379-390 (1973)). However this inhibitor is 
not useful either in vivo or in vitro for the uses cited in 
this application. Since it is an alkylating agent, it could 
not be used in vivo due to its potential carcinogenicity. 
In vitro, it could not be used in the presence of any 40 
peptides, proteins, or other molecules containing nu-
cleophilic groups since alkylation of the nucleophilic 
groups would alter the activity, properties, and function 
of the peptide, protein or other molecule. Therefore, a 
need exists for a less reactive type of heterocyclic serine 
45 
protease inhibitor. The novel reversible heteocyclic 
serine protease inhibitors of this invention have the 
following structural formula: 
ase. The R group must be uncharged and hydrophobic. 
One or more of the carbons in the R group could be 
replaced by 0, S, NH and other such atomic groupings 
as long as the R group maintains its hydrophobic char-
acter. 
The following novel compounds are representative 
of this invention: 
2-trifluoromethyl-4H-3,1-benzoxazine-4-one, 










Inhibition constants (Ki) for the inhibition of PP elas-
tase, HL elastase, chymotrypsin and cathepsin G have 
been measured and are published (cf. Teshima, Griffin 
and Powers, J. Biol. Chem. 257, pp 5085-5091 (1982)). 
The applicant was director of the research coauthored 
by others. It has already been described above how to 
use the Ki values to choose an inhibitor with specificity 
toward a certain enzyme or which is a general inhibitor. 
To use the above identified inhibitors in vitro, they 
are dissolved in an organic solvent such as dimethylsulf-
oxide or ethanol and are added to an aqueous solution 
containing the protease which is to be inhibited such 
that the final concentration of organic solvent is 25% or 
less. The inhibitors may also be added as solids or in 
suspension. 
It is well known in the literature that in vitro activity 
of elastase inhibitors correlates with in vivo activity in 
animal models of emphysema. Thus the novel inhibitors 
described here should be useful for the treatment of 
emphysema. Elastase inhibitors have been used orally, 
by injection or by instillation in the lungs in animal 
studies (cf. Powers, Am. Rev. Respir. Dis., 127, s54-s58 
(1983) and references cited therein). The inhibitors de-
scribed above can be used by any of these routes. 
Several other diseases also involve tissue destruction 
by proteases such as elastase-like and chymotrypsin-like 
enzymes (cf. Powers, Ad. in Chem., 198, 347-367 
(1982)). These include pancreatitis, inflammation, and 






50 tween in vitro activity of elastase and chymotrypsin 
inhibitors and in vivo activity in animal models have not 
yet be made for these diseases, it is likely that such 
correlations will be made shortly. And the novel inhibi-
tors can then be used in any cases where such correla-
wherein 55 tions are made. 
The following example is given to illustrate the in-
vention and is not intended to limit it in any manner. 
Z is selected from the group consisting of CO, SO, 
S02, CCI, and CF, 
Y is selected from the group consisting of 0, S, and 
NH, 
X is selected from the group consisting of N and CH, 60 
and 
R is selected from the group consisting of C1-6 alkyl 
(such as methyl, ethyl, and propyl), C14 alkyl con-
taining a phenyl (such as benzyl), and C1-6 fluoroal-
kyl (such as trifluoromethyl, pentafluoroethyl, and 65 
heptafluoropropyl). 
The Z group must be electrophilic since it interacts 
with the active site serine OH group of the serine prote-
EXAMPLE 1 
Preparation of N-Heptafluorobutanoylanthranilic Acid 
Thiobenzyl Ester 
Anthranilic acid thiobenzyl ester hydrochloride (200 
g) was acylated with heptafluoro butyric anhydride 
(322 mg). The product was purified by silica gel column 
chromatography using chloroform as a solvent to give 
256 mg of material with mp 50-51 deg centigrade. Anal. 
Calcd. for C1sH12N02F1S: C, 49.12; H, 2.75; N, 3.19. 




Other illustrative examples are incorporated by refer-
ence herein in the Teshima, Griffin and Powers publica-
tion, cited above. 
What is claimed is: 
1. A compound of the formula: 5 
2-(R-Y-X)-C6H4-CO-S-R' 
wherein 
R' is selected from the group consisting of C1-6 alkyl 10 
and C1-4 alkyl with an attached phenyl group, 
Xis NH, 
Yis CO, 
R is selected from the group consisting of C1.5 alkyl, 
C1.s fluorinated alkyl, and C1.5 alkoxy. 15 
2. A process for the inhibition of enzymatic activity 
of elastase, chymotrypsin and other serine proteases 
with similar substrate specificity, comprising the step of 
adding to a medium containing the protease an amount 
of an inhibitor effective to inhibit said activity, the in- 20 












R' is selected from the group consisting of C1-6 alkyl 
and C1-4 alkyl with an attached phenyl group, 
Xis NH, 
Y is CO, and 
R is selected from the group consisting of C1.5 alkyl, 
C1.5 fluorinated alkyl, and C1.5 alkoxy. 
3. A method of treating emphysema in animals, com-
prising the step of administering to said animal a thera-




R' is selected from the group consisting of C1-6 alkyl 
and C1-4 alkyl with an attached phenyl group, 
Xis NH, 
Y is CO, 
R is selected from the group consisting of C1.5 alkyl, 
C1.5 fluorinated alkyl, and C1.5 alkoxy. 
* * * * * 
